Franchini Massimo, Zaffanello Marco, Veneri Dino
Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy.
Thromb Haemost. 2005 Jun;93(6):1027-35. doi: 10.1160/TH05-01-0032.
Recombinant activated factor VII (rFVIIa, NovoSeven) has been successfully used to treat bleeding episodes in patients with antibodies against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired haemostatic abnormalities. Based on a literature search, this review examines the current knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer and less well-characterised clinical applications.
重组活化凝血因子 VII（rFVIIa，诺其）已成功用于治疗患有抗凝血因子 VIII 和 IX 抗体的患者的出血发作。近年来，rFVIIa 还被用于治疗多种先天性和获得性止血异常导致的难以控制的出血。基于文献检索，本综述考察了关于 rFVIIa 治疗的现有知识，范围从现已标准化的用途到更新的、特征尚不明确的临床应用。
